作者
Wassim Abida, Akash Patnaik, David Campbell, Jeremy Shapiro, Alan H Bryce, Ray McDermott, Brieuc Sautois, Nicholas J Vogelzang, Richard M Bambury, Eric Voog, Jingsong Zhang, Josep M Piulats, Charles J Ryan, Axel S Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Celestia S Higano, Laurence E Krieger, Cora N Sternberg, Simon P Watkins, Darrin Despain, Andrew D Simmons, Andrea Loehr, Melanie Dowson, Tony Golsorkhi, Simon Chowdhury, TRITON2 investigators
发表日期
2020/11/10
期刊
Journal of Clinical Oncology
卷号
38
期号
32
页码范围
3763-3772
出版商
American Society of Clinical Oncology
简介
PURPOSE
BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated with a BRCA alteration treated with rucaparib 600 mg twice daily in the phase II TRITON2 study.
METHODS
We enrolled patients who progressed after one to two lines of next-generation androgen receptor–directed therapy and one taxane-based chemotherapy for mCRPC. Efficacy and safety populations included patients with a deleterious BRCA alteration who received ≥ 1 dose of rucaparib. Key efficacy end points were objective response rate (ORR; per RECIST/Prostate Cancer Clinical Trials Working Group 3 in patients with measurable disease as assessed by blinded, independent radiology review and by investigators) and locally assessed prostate …
学术搜索中的文章
W Abida, A Patnaik, D Campbell, J Shapiro, AH Bryce… - Journal of Clinical Oncology, 2020